Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium

The current gold standard for prostate cancer treatment is androgen deprivation therapy and antiandrogenic agents. However, adverse cardiovascular events including heart failure can limit therapeutic use. Istaroxime, which combines Na(+)-K(+)-ATPase (NKA) inhibition with sarco/endoplasmic reticulum...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncotarget
Main Authors: Wallner, Markus, Khafaga, Mounir, Kolesnik, Ewald, Vafiadis, Aris, Schwantzer, Gerold, Eaton, Deborah M., Curcic, Pero, Köstenberger, Martin, Knez, Igor, Rainer, Peter P., Pichler, Martin, Pieske, Burkert, Von Lewinski, Dirk
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2017
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5564766/
https://ncbi.nlm.nih.gov/pubmed/28514771
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17540
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki